文献速递心律失常心力衰竭与心肌病

致病性桥粒斑蛋白变异患者心肌炎样发作的预后作用及其治疗

Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants.
PubMed 文献 · Circulation · 2025-08-20

本研究为观察性队列研究,纳入DSP-ERADOS网络中1014例致病性或可能致病性DSP变异患者,评估心肌炎样发作复发及治疗对室性心律失常和心衰结局的影响。结果显示,对首次心肌炎样发作进行免疫抑制治疗与室性心律失常和心衰结局风险降低相关,风险比分别为0.18和0.09,但与复发发作减少无关。

要点

  • 17.5%的DSP变异患者发生至少一次心肌炎样发作。
  • 首次发作免疫抑制治疗与室性心律失常和心衰风险降低相关。
  • 非甾体抗炎药或秋水仙碱治疗未影响结局。

核心结论

  • 对DSP变异患者的心肌炎样发作进行免疫抑制治疗与室性心律失常或心衰复合结局改善相关,支持未来在DSP队列中开展前瞻性评估。

研究设计与样本

  • 观察性队列研究,使用DSP-ERADOS网络中截至2024年4月30日在31家机构入组的全部致病性或可能致病性DSP变异患者,共1014例(62.4%女性;平均年龄40.4±17.4岁;47.1%为先证者)。

主要发现

  • 177例(17.5%)患者经历至少1次记录到的心肌炎样发作,其中63例(35.6%)接受免疫抑制治疗。
  • 对首次记录到的心肌炎样发作进行免疫抑制治疗,在中位随访6.4年(95%CI 4.0-10.5)期间与室性心律失常风险降低相关(HR 0.18,95%CI 0.07-0.45,P<0.001)。
  • 对首次记录到的心肌炎样发作进行免疫抑制治疗,在中位随访6.4年(95%CI 4.0-10.5)期间与心衰结局风险降低相关(HR 0.09,95%CI 0.02-0.39,P=0.001)。
  • 免疫抑制治疗后的风险与无心肌炎样发作史的患者相当,但与初始免疫抑制完成后复发发作减少无关(HR 0.85,95%CI 0.47-1.54,P=0.599)。
  • 非甾体抗炎药或秋水仙碱治疗未影响结局。

临床怎么用

  • 对于致病性或可能致病性DSP变异患者,首次心肌炎样发作时考虑免疫抑制治疗可能改善室性心律失常和心衰结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammatory, myocarditis-like episodes precede and are associated with higher risk of sustained ventricular arrhythmias and heart failure in patients with pathogenic or likely pathogenic desmoplakin (DSP) variants. Whether the recurrence and treatment of myocarditis-like episodes influence the outcomes in this population is unknown. This study aimed to assess the prognostic impact of the recurrence and treatment of myocarditis-like episodes in patients with pathogenic or likely pathogenic DSP variants. METHODS: The study was designed as an observational cohort study using all patients with pathogenic or likely pathogenic DSP variants in the DSP-ERADOS Network (Desmopakin Specific Effort for a Rare Disease Outcome Study) enrolled at 31 institutions up until April 30, 2024. Survival from ventricular arrhythmia and heart failure end points and recurrent myocarditis-like episodes was evaluated for both first and recurrent documented myocarditis-like episodes and the impact of immunosuppressive treatment on outcomes assessed. RESULTS: A total of 1014 patients with pathogenic or likely pathogenic DSP variants (62.4% female; mean age, 40.4±17.4 years; 47.1% probands) were included. Among them, 177 individuals (17.5%) experienced ≥1 documented myocarditis-like episode, with 63 of them (35.6%) receiving immunosuppressive treatment. Immunosuppressive treatment of the first documented myocarditis-like episode was associated with reduced risk of ventricular arrhythmia and heart failure outcomes (hazard ratio, 0.18 [95% CI, 0.07-0.45]; P<0.001; and hazard ratio, 0.09 [95% CI, 0.02-0.39; P=0.001, respectively) over a median follow-up of 6.4 years (95% CI, 4.0-10.5). This risk was comparable to that of patients with no history of myocarditis-like episode but did not correlate with a reduction in recurrent episodes after completion of initial immunosuppression (hazard ratio, 0.85 [95% CI, 0.47-1.54]; P=0.599). In contrast, nonsteroidal anti-inflammatory drugs or colchicine treatment did not influence outcomes. CONCLUSIONS: Immunosuppressive treatment of myocarditis-like episodes in DSP patients was associated with improved combined ventricular arrhythmia or heart failure outcomes, supporting future prospective evaluation in DSP cohorts.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Gasperetti A, Muller SA, Peretto G, et al. Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. Circulation. 2025. PMID: 40832715. doi:10.1161/CIRCULATIONAHA.125.073919

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。